Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

s received seven years of orphan exclusivity in the United States and ten years of market exclusivity in the E.U.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  ArroGen Group, an integrated advanced ... Molecular Identification™ (FMID) technology Aug. 2-8 at the ... Sacramento, Calif. FMID, ... law enforcement agents, district attorneys and government agencies ... By analyzing chemical residues on fingerprints ...
(Date:8/3/2015)... , August 3, 2015 At ... Portland Hospital waved the shortfall of Jude ... stand normally for the first time.      ... http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective Dorsal ... allowing him to carry out his wish to kick ...
(Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... the 35 th Annual Canaccord|Genuity Growth Conference in ... Petit, Chairman and CEO, William C. Taylor , ...
(Date:8/3/2015)... ... August 03, 2015 , ... The ... processed to get such derivatives as ethylbenzene, a precursor to styrene, used to ... the automotive industry for the production of tyres and other components. Thus, growth ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3
... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
... ,,, ... 26, 2010, QIAGEN N.V. (NASDAQ: ... Prime Standard: QIA [, http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ... an agreement with Roche Molecular Systems,Inc., ...
... increase crop yields and productivity, create sustainable forests and new medicines, and ... in the world,s poorest countries, will be among the recurring themes of ... Congress, June 6-11, 2010 , at the America,s Center ... , , ...
Cached Biology Technology:CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 2QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 3QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 5QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 6Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 2Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 3
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... uncovered an important step in how herpes simplex virus, ... to gain entry into healthy cells and infect them. ... the effectiveness of monitoring these protein interactions using biomolecular ... the National Academy of Sciences, provide a better understanding ...
... Access publisher for Physics, Mathematics and Computer Science, ... DESY high-energy physics laboratories. Under these agreements ... all research published by their investigators in the ... PMC Physics A is edited by professor Ken ...
... connect silicon circuits with brains are under intensive ... commercial application in many areas, according to a ... Berger of the University of Southern California chaired ... of Research and Development in Brain-Computer Interfaces," published ...
Cached Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Top physics laboratories sign up to open access with PhysMath Central 2Brain-computer link systems on the brink of breakthrough, study finds 2
... of the human Topoisomerase II gene. ... state of nucleic acids by passing an intact ... a separate DNA helix (1,2) . As a ... enzyme can relax negatively or positively supercoiled DNA, ...
... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
... is a genetically engineered Klenow polymerase in which ... removed, leaving only the 5 to 3 polymerase ... Klenow Fragment the enzyme of choice for isotopic ... random primed method, and for DNA sequencing by ...
Request Info...
Biology Products: